Berlin, Germany, and New York, USA – October 2025 – StratifAI, the AI precision oncology company behind the Polaris™ platform, today announced its selection for the Memorial Sloan Kettering (MSK) iHub Challenge 2025 Cohort program. This engagement provides StratifAI access to MSK’s extensive clinical datasets and oncology expertise, enabling the company to advance validation of Polaris™, its multimodal AI platform designed to transform routine clinical data into powerful, scalable biomarkers that guide cancer treatment decisions.
Building a new standard in biomarker validation
For decades, biomarker discovery has been limited by high costs, slow processes, and narrow scope. StratifAI overcomes these barriers with Polaris™, a fully digital, multimodal AI platform that transforms routine clinical data, already integral to everyday care, into novel biomarkers that guide treatment decisions. By eliminating the need for costly and specialized inputs, Polaris™ is designed for global scalability and broad access to precision oncology. Through MSK’s resources, StratifAI will further validate Polaris™ on real-world clinical data as it advances toward regulatory approval and guideline inclusion in the EU and US.
Pathways beyond the challenge
The collaboration aims not only to accelerate validation during the Challenge but also hopes to establish a foundation for extended collaboration. StratifAI and MSK hope to build pathways that support ongoing validation of Polaris™ in diverse clinical contexts, strengthening its utility for oncologists worldwide.
Focus on breast cancer recurrence risk
This collaboration builds on StratifAI’s ongoing validation of Polaris™ Breast, a test designed to assess recurrence risk in early-stage breast cancer. By combining exclusive data access partnerships across Europe and the United States, StratifAI is generating the robust clinical evidence required for regulatory approval, reimbursement, and integration into international treatment guidelines.
